Avacta Group (LON:AVCT) Trading Up 14.7% - Time to Buy?

Key Points

• Avacta Group's stock price rose by 14.7%, reaching GBX 54.50 ($0.73), with trading volume increasing by 181% compared to its average daily volume.
• The biotechnology firm reported a negative earnings per share of GBX (8.54) (($0.11)) for the quarter, with analysts predicting a further decline to -9.90 for the current year.
• Despite recent stock performance, the company has a significant negative net margin of 114.45% and a high debt-to-equity ratio of 52.53, raising concerns about its financial stability.

Avacta Group Plc (LON:AVCT - Get Free Report)'s stock price traded up 14.7% during mid-day trading on Wednesday . The company traded as high as GBX 54.85 ($0.73) and last traded at GBX 54.50 ($0.72). 5,689,326 shares changed hands during mid-day trading, an increase of 181% from the average session volume of 2,025,171 shares. The stock had previously closed at GBX 47.50 ($0.63).

Avacta Group Stock Down 7.4%

The firm has a market capitalization of £181.21 million, a price-to-earnings ratio of -6.14 and a beta of 1.12. The business has a 50 day simple moving average of GBX 35.08 and a 200-day simple moving average of GBX 37.67. The company has a debt-to-equity ratio of 52.53, a quick ratio of 4.96 and a current ratio of 1.29.

Avacta Group (LON:AVCT - Get Free Report) last released its quarterly earnings results on Friday, June 6th. The biotechnology company reported GBX (8.54) (($0.11)) earnings per share for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. On average, equities analysts expect that Avacta Group Plc will post -9.9011833 EPS for the current year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).